Navigation Links
EpiVax-Novozymes Tregitope-Albumin Fusion Moves 'Paradigm-Shifting' Treatment for Diabetes Closer to Clinical Trials
Date:2/12/2013

PROVIDENCE, R.I., Feb. 12, 2013 /PRNewswire/ -- EpiVax, Inc. is pleased to announce a new Collaborative Research Agreement with Novozymes Biopharma. The collaboration will enable EpiVax to rapidly advance its Tregitope immune-modulating technology as a potential treatment for autoimmune diseases. When used as a buffering agent, albumin has excellent safety and pharmacokinetic profiles. Fusing Tregitopes to Novozymes' proven albumin-based half-life extension platform will create a safe and effective vehicle for the application of Tregitopes to multiple problems in the areas of autoimmunity, transplantation, and allergy.

(Logo: http://photos.prnewswire.com/prnh/20121116/NE15175LOGO )

Tregitopes, discovered by Anne De Groot and Bill Martin at EpiVax, are linear sequences of amino acids contained within the framework of monoclonal antibodies and immunoglobulin G; the original finding was published in the journal Blood in 2008. Since their discovery, EpiVax has compiled substantial evidence linking Tregitopes to the activation of natural regulatory T cells. By selectively activating these natural regulatory T cells, Tregitopes can dampen unwanted immune responses. Preliminary studies carried out by EpiVax and collaborators indicate that Tregitopes may be useful for inducing tolerance to transplants, protein drugs, and blood replacement therapies, as well as for the treatment of allergies. EpiVax believes Tregitopes may explain the effectiveness of intravenous immunoglobulin G (IVIG), widely utilized as an autoimmune treatment (a $4B annual market).

The initial disease target for Tregitope therapy with the albumin-Tregitope fusion will be Type 1 diabetes (T1D). Each year, more than 13,000 young people are diagnosed with T1D. Islet replacement therapy is in the experimental stage for individuals with advanced disease, and EpiVax believes the albumin-Tregitope fusion will facilitate this novel treatment for individuals in later stages of T1D.

Tregitopes act as a natural immune system "off switch" and have been shown in standard preclinical models to "reset" immune responses away from autoimmunity and towards tolerance. "Developing more specific therapies to promote tolerance … is a critical component of a comprehensive approach to T1D," said Julia L. Greenstein , Ph.D., VP of Cure Therapies for JDRF, whose previous funding helped EpiVax derive preliminary data to support recent NIH awards.  "[Tregitopes] may have the potential to reduce the harmful immune responses to the insulin-producing beta cells, thereby preserving the body's ability to make its own insulin." 

NIH SBIR grants coupled with private foundation funds have brought total pre-clinical funding for Tregitopes to more than $6M in the past 4 years.

FULL ARTICLE - http://bit.ly/EpiVaxNovoPR

Contact:
Anthony Marcello
1-401-272-2123
amarcello@epivax.com
www.epivax.com


'/>"/>
SOURCE EpiVax, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Launches New Take-Apart Laparoscopic Scissors
2. CareFusion Reports First Half Fiscal 2013 Results
3. CareFusion Files Fiscal 2012 Form 10-K
4. B. Braun Smart Infusion Pump Technology Advances Patient Safety and Treatment Efficiency
5. Global Spinal Nonfusion Market to Grow to $1 Billion by 2017, Despite Challenges
6. Hospira and Q Core Medical Sign International Distribution Agreement for Sapphire Infusion System
7. CareFusion Launches New Preoperative Cleansing Program For In-Home Patient Use
8. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
9. Practice Fusion Announces Free EMR for iPad in Beta
10. CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
11. CareFusion To Report Preliminary Fiscal 2013 First Quarter Results On Nov. 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 The Board of Directors of ... General Meeting, which is to take place on Thursday, April 27, ... Lund, Sweden . ... Please see the attached notification, which is being announced ... NeuroVive Pharmaceutical AB (Publ) The Board Of Directors ...
(Date:3/22/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Respiratory care devices ... over the next decade to reach approximately $38.27 billion by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... , March 22, 2017 Ampio ... the development of Ampion™, a low molecular weight ... today announced that it is re-issuing its previous release ... incorporate certain disclosures that are required under the ... below are these additional disclosures along with the ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, a privately ... completion of the strategic executive team expansion needed to further optimize growth and ... executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... It’s that ... means many students are thinking about summer internships , which can be frustrating ... , The pros at Garden Media Group, a boutique public relations firm outside of ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Leaders Engaged ... and fatal diseases in opposition to the President’s Fiscal Year 2018 Federal ... services, and hope for the most vulnerable among us. , The proposed budget ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored to ... All events will be located in the Main West Entrance of The Boulevard ... ID event. No appointment is necessary and each child with a parent or guardian ...
(Date:3/23/2017)... ... , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call to ... the creation of published author, Desiree M Webb, a registered nurse, minister of music, ... happily married to her husband, Paul, for over twenty-nine years. Desiree enjoys writing, ...
Breaking Medicine News(10 mins):